海外の治験の状況「1」での検索結果
11979件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
- Type 1 Diabetes Mellitus
- Australia, Austria, Canada, France, Germany, Hungary, Israel, Italy, Puerto Rico, Spain, United States
- 2019-02-04
Not Recruiting
- A trial investigating the effect on blood glucose after the injection of fast-acting insulin aspart (Fiasp®) in comparison to insulin aspart (NovoRapid®) around exercise in participants with type 1 diabetes
- ;E10 - Type 1 diabetes mellitus
- Austria, United Kingdom
- 2019-06-12
Not recruiting
- Comparison of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil and Insulin Aspart
- Type 1 Diabetes Mellitus (T1DM)
- Germany
- 2019-10-16
Not Recruiting
- Digital Diabetes Clinic
- ;E10 - Type 1 diabetes mellitus
- Germany
- 2019-10-07
Not Recruiting
- Observational analysis of glycaemic, dietary and GPS data of Team Novo Nordisk Professional cyclists under race conditions
- ;E10 - Type 1 diabetes mellitus
- Slovenia
- 2020-01-13
Not Recruiting
- Observational analysis of glycaemic, dietary and GPS data of Team Novo Nordisk Professional cyclists during a training camp
- ;E10 - Type 1 diabetes mellitus
- Spain
- 2020-01-13
Recruiting
- SmartTouch Catheter for Left Anterior Line - SmarT Line Study
- Persistent Atrial Fibrillation
- Germany
- 2014-08-14
Not Recruiting
- Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
- Type1-Diabetes MedDRA version: 17.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- France, Germany, Hungary, Japan, Mexico, Poland, Russian Federation, Spain, United States
- 2014-08-07
Recruiting
- Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
- Metastatic Renal Cell Carcinoma (mRCC)
- Austria, Belgium, France, Italy, Spain, United Kingdom
- 2014-07-02
Not Recruiting
- Treatment of low blood sugar with glucagon among patients with type 1 diabetes mellitus who have an impaired insulin production.
- Patients with type 1 diabetes mellitus br>MedDRA version: 17.0 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Denmark
- 2014-06-26
Not recruiting
- Pregnancy Chances in Classic Galactosemia
- Galactosemias;Primary Ovarian Insufficiency
- Netherlands
- 2014-03-13
Recruiting
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Once-Daily Administration Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy
- Diabetic Nephropathy;N08.3 - Glomerular disorders in diabetes mellitus;E11.2 - Non-insulin-dependent diabetes mellitus; With renal complications
- Argentina, Australia, Canada, Germany, Hong Kong, Italy, Korea, Republic of, Malaysia, Peru, Poland, Romania, Spain, United States
- 2015-01-09
Not recruiting
- Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
- Epithelial Ovarian Cancer;Epithelial Ovarian Cancer;Epithelial Ovarian Cancer;Epithelial Ovarian Cancer
- Australia, Austria, Belarus, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Korea, Republic of, Latvia, Lithuania, Poland, Romania, Russian Federation, Sweden, Thailand, Ukraine, United States
- 2012-01-17
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY
- -E112 Non-insulin-dependent diabetes mellitus, with renal complications Non-insulin-dependent diabetes mellitus, with renal complications;Non-insulin-dependent diabetes mellitus, with renal complications
- Australia, Brazil, Canada, Germany, India, Italy, Korea South, Poland, Romania, Spain, United States
- 2013-12-27
Authorised
- A study to investigate the effects of the course of first-line therapy with gemcitabine on the success of second-line therapy with NAL-IRI combination therapy
- locally advanced or metastatic pancreatic cancer after failure of a gemcitabine/nab-paclitaxel 1st-line treatment MedDRA version: 20.0 Level: LLT Classification code 10033604 Term: Pancreatic cancer System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10033607 Term: Pancreatic cancer recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2017-10-09
Authorised
- Arginine as medication to improve outcome in patients with galactosemia
- Classic galactosemia;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Netherlands
- 2017-09-13
Authorised
- A multicenter randomized phase 2 study to compare the efficacy and safety of avelumab versus standard second line treatment, in patients with metastatic colorectal cancer (MMR) after first line treatment progression.
- COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI);Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2017-07-12
Not recruiting
- The Effect of Arginine on Classic Galactosemia
- Classic Galactosemia
- Netherlands
- 2018-06-05
Authorised
- FOLFIRI + panitumumab in second-line in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line
- Subjects treated in first-line with panitumumab and FOLFOX and having at least achieved stable disease with wild type RAS metastatic Colorectal Cancer confirmed in liquid biopsies before starting second line treatment will be screened for this trial. Only subjects who have interrupted panitumumab for MedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2018-04-09
Not recruiting
- To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.
- Melanoma Metastatic;BRAF V600 Mutation;Melanoma Metastatic;BRAF V600 Mutation;Melanoma Metastatic;BRAF V600 Mutation
- Italy
- 2018-03-28
